Yazar "Serin, İstemi" için listeleme
-
Assesment of patient's perspective on treatment free remission in CML: A Turkish multicenter cohort
Mutlu, Yaşa Gül; Güvenç, Birol; Serin, İstemi; Balık Aydın, Berrin; Alacacıoğlu, İnci; Güven, Serkan; Sevindik, Ömür Gökmen (American Society of Hematology, 2022)Treatment free remission (TFR) is one of the main goals of therapy in Chronic Myeloid Leukemia (CML). Patient perspective and expectations have an indicative effect on discontinuation decisions. We analyzed 116 CML patients' ... -
Charlson comorbidity index (CCI) in diffuse large B-cell lymphoma: A new approach in a multicenter study
Eren, Rafet; Serin, İstemi; Atak, Süheyla; Pirdal, Betül Zehra; Nizam, Nihan; Gemici, Aliihsan; Aydın, Demet; Demirel, Naciye; Doğan, Esma Evrim; Yokuş, Osman (Springer, 2023)Purpose: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of adult lymphomas. The incidence of DLBCL increases with age and has a fairly rapid fatal course without treatment. Patients often have difficulty ... -
Comparison of efficacy and safety of generic plerixafor vs original plerixafor in the mobilization of myeloma patients
Sevindik, Ömür Gökmen; Bilgen, Hülya; Serin, İstemi; Melek, Elif; Karakuş, Volkan; Çerçi, Kübra; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Sadri, Sevil; Beköz, Hüseyin Saffet; Kaynar, Leylagül (American Society of Hematology, 2022)Introduction The commonest indication for an Autologous Stem Cell Transplantation (ASCT) is still Multiple Myeloma. A successful mobilization of hematopoietic stem cells (HSC) is a sine qua non of ASCT. The introduction ... -
DNA repair genes and chronic myeloid leukemia: ERCC2 (751), XRCC1 (399), XRCC4-Intron 3, XRCC4 (-1394) gene polymorphisms
Özdilli, Kürşat; Pehlivan, Mustafa; Serin, İstemi; Oğuz Savran, Fatma; Tomatır, Ayşe Gaye; Pehlivan, Sacide (Mattioli 1885, 2021)To the editor. Chronic myeloid leukemia (CML), which is characterized by the overproduction of mature cells in the granulocytic series, is included in the group of chronic myeloproliferative neoplasms.1 It is the first ... -
First-line usage of daratumumab, lenalidomide, dexamethasone (DRd) combination in a case of castleman disease variant of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (CD-POEMS)
Sevindik, Ömür Gökmen; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Serin, İstemi (Lippincot Williams & Wilkins, 2022)Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (POEMS) is a rare paraneoplastic syndrome of an underlying plasma cell disorder (PCD).1 Castleman disease (CD), itself, can ... -
Gilteritinib (XOSPATA (R)) in Turkey: Early access program results
Doğu, Mehmet Hilmi; Tekgündüz, Ali İrfan Emre; Deveci, Burak; Korkmaz, Gülten; Cömert, Melda; Sevindik, Ömür Gökmen; Yokuş, Osman; Serin, İstemi (Mattioli 1885, 2023)Background And Objectives: Gilteritinib (XOSPATA (R), Astellas) is a type I oral FLT3 inhibitor, a tyrosine kinase AXL inhibitor, involved in both c-Kit and FMS-like tyrosine kinase 3 (FLT3) resistance. In the phase 3 ... -
Otolog kök hücre transplantasyonunda Sitomegalovirüs (CMV) ve Hepatit B (HBV) reaktivasyonu: Tek merkez deneyimi
Gemici, Aliihsan; Beköz, Hüseyin Saffet; Sevindik, Ömür Gökmen; Sadri, Sevil; Serin, İstemi; Erol, Vedat Buğra; Sargın, Fatma Deniz; Kaynar, Leylagül (Lösemi Lenfoma Miyelom Derneği, 2022)Amaç: Sitomegalovirüs (CMV) reaktivasyonu allojenik hematopoetik kök hücre transplantasyo- nu sırasında sık görülür. Hepatit B reaktivasyonu (HBV), akut hepatit ve fulminan karaciğer yet- mezliği veya sadece HBV DNA düzeyinde ... -
Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?
Serin, İstemi; Sevindik, Ömür Gökmen; Balık Aydın, Berrin; Melek, Elif; Mutlu, Yaşa Gül; Bilgen, Hülya; Beköz, Hüseyin; Kaynar, Leylagül (Elsevier Ltd, 2023)Plerixafor increases stem cell mobilization by reversibly binding to the chemokine receptor CXCR4. In our study, we examined the results of mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) and ... -
Quality of life assessment with EORTC QLQ in patients with hodgkin lymphoma: Multicenter study
Gemici, Aliihsan; Serin, İstemi; Erol, Vedat Buğra; Doğu, Mehmet Hilmi; İnce, İdris; Eren, Rafet; Tekinalp, Atakan; Karakuş, Volkan; Sevindik, Ömür Gökmen (Ankara Hematology Oncology Association, 2022)Aim: The aim of our study is to obtain data on the quality of life (QoL) in Hodgkin lymphoma (HL) patients in a representative sample of the general population of Turkey with the help of the EORTC QLQ-C30 and QLQ-HL27 ... -
Quality of life assessment with EORTC QLQ in patients with multiple myeloma: Multicenter study
Gemici, Aliihsan; Serin, İstemi; Erol, Vedat Buğra; Doğu, Mehmet Hilmi; İnce, İdris; Eren, Rafet; Tekinalp, Atakan; Karakuş, Volkan; Koç Erol, İklil Nur; Arslan, Zeynep Ece; Tay, Zekiye Nur; Tuncer, Elif Nur; Sevindik, Ömür Gökmen (Galenos Publishing House, 2022)Objective: Both the length of the treatment period and the diversity of the agents used in the treatment significantly affect the quality of life (QoL) of the patients with multiple myeloma (MM). With the aid of the EORTC ... -
A real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia
Gemici, Aliihsan; Özkalemkaş, Fahir; Doğu, Mehmet Hilmi; Tekinalp, Atakan; Alacacıoğlu, İnci; Güney, Tekin; İnce, İdris; Gedük, Ayfer; Akgün Çağlıyan, Gülsüm; Maral, Senem; Serin, İstemi; Gündüz, Eren; Karakuş, Volkan; Beköz, Hüseyin Saffet; Eren, Rafet; Pınar, İbrahim Ethem; Güneş, Ahmet Kürşad; Sargın, Fatma Deniz; Sevindik, Ömür Gökmen (CIG Media Group, 2021)Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients ... -
Relaps/refrakter lenfoma (mantle hücreli lenfoma hariç) hastalarında lenalidomid bazlı tedavi sonuçları: Çok merkezli sonuçlar
Amaç: Lenfomalar, çoğunlukla B hücre kökenli heterojen bir hastalık grubunu temsil eder. Lenalidomid, kemo-immünoterapötik ajanlara talidomidin yapısal bir analoğu olarak dahil edilmiştir. Bu çalışmada amaç, mantle hücreli ... -
To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission
Sevindik, Ömür Gökmen; Mergen, Mahmut; Mergen, Sena; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Serin, İstemi (Springer Science and Business Media Deutschland GmbH, 2022)Dear Editor, Acute myeloid leukemia is the most common sub-type of acute leukemia in adulthood [1]. It has a detrimental prognosis with conventional combination chemotherapy, mainly with anthracyclines and cytarabine. ...